PALB2 and breast cancer: Six out of 12 patients who received ≥6 cycles of maintenance therapy had BRCA1/2 alterations on germline testing, while two additional patients in this group had DDR pathway alterations detected on Foundation One NGS, including a patient with cutaneous squamous cell cancer and a pathogenic PALB2 mutation and a patient with breast cancer and a pathogenic FANCA mutation.